BANCO SANTANDER S.A. (SAN)
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
📈 **POSITIVE** • Medium confidence analysis (62%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (75%) **Content type:** Clinical